Literature DB >> 10195483

Emergency department management of occupational exposures to HIV-infected fluids.

S S Torbati1, D A Guss.   

Abstract

The emergency department is where many healthcare workers will seek medical advice and care after a potential exposure to bodily fluids contaminated with the human immunodeficiency virus (HIV). The estimated risk of HIV infection in healthcare workers with percutaneous exposures to HIV-infected blood is estimated at 0.3% to 0.32%. Zidovudine (AZT) post-exposure prophylaxis has been associated with a 79% reduction in the risk of seroconversion in a case-control study sponsored by the Center for Disease Control and Prevention (CDC), and has become part of the standard prophylactic treatment for patients with occupational HIV exposure. This article reviews the current CDC recommendations as well as our institutional practice guidelines for the management of healthcare workers who are exposed to potential or confirmed HIV-infected fluids.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10195483     DOI: 10.1016/s0736-4679(98)00188-7

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  3 in total

Review 1.  Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure.

Authors:  T N Young; F J Arens; G E Kennedy; J W Laurie; G w Rutherford
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Prevalence of occupational exposure to blood and body secretions and its related effective factors among health care workers of three Emergency Departments in Tehran.

Authors:  Davood Farsi; Mohammad A Zare; Sayed A Hassani; Saeed Abbasi; Afsoon Emaminaini; Peyman Hafezimoghadam; Mahdi Rezai
Journal:  J Res Med Sci       Date:  2012-07       Impact factor: 1.852

3.  A tailored health surveillance program unveils a case of MALT lymphoma in an HCV-positive health-care worker.

Authors:  Venerando Rapisarda; Andrea Marconi; Saverio Candido; Daria Nicolosi; Mario Salmeri; Pietro Gangemi; Lidia Proietti; Demetrios A Spandidos; Massimo Bracci; Cettina Fenga; Massimo Libra
Journal:  Oncol Lett       Date:  2012-11-15       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.